retatrutide
Jump to navigation
Jump to search
Indications
- investigational weight loss drug
* weight loss at 24 weeks 17% with 12 mg (effectiveness dose-dependent)
Dosage
- start 2-4 mg
- max 12 mg
Adverse effects
Mechanism of action
- 3 hormone receptor agonist
More general terms
References
- ↑ Zoler ML Triple Agonist Retatrutide Hits New Weight-Loss Highs. Medscape. June 26, 2023 https://www.medscape.com/viewarticle/993714
Jastreboff AM, Kaplan LM, Frias JP et al Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2024. Jun 26. PMID: https://www.ncbi.nlm.nih.gov/pubmed/37366315 https://www.nejm.org/doi/full/10.1056/NEJMoa2301972